Bluebird bio Inc - Asset Resilience Ratio
Bluebird bio Inc (BLUE) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BLUE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2023)
This chart shows how Bluebird bio Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Bluebird bio Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bluebird bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bluebird bio Inc (BLUE) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bluebird bio Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bluebird bio Inc Industry Peers by Asset Resilience Ratio
Compare Bluebird bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Bluebird bio Inc (2011–2023)
The table below shows the annual Asset Resilience Ratio data for Bluebird bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $619.16 Million | -- |
| 2022-12-31 | 12.13% | $67.32 Million | $554.90 Million | -11.17pp |
| 2021-12-31 | 23.30% | $138.34 Million | $593.79 Million | -23.50pp |
| 2020-12-31 | 46.80% | $833.55 Million | $1.78 Billion | +1.69pp |
| 2019-12-31 | 45.11% | $779.25 Million | $1.73 Billion | +1.29pp |
| 2018-12-31 | 43.82% | $982.73 Million | $2.24 Billion | +15.85pp |
| 2017-12-31 | 27.97% | $531.60 Million | $1.90 Billion | -10.08pp |
| 2016-12-31 | 38.05% | $425.49 Million | $1.12 Billion | +2.77pp |
| 2015-12-31 | 35.29% | $353.68 Million | $1.00 Billion | +12.71pp |
| 2014-12-31 | 22.58% | $125.71 Million | $556.74 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $224.39 Million | -- |
| 2011-12-31 | 11.34% | $3.51 Million | $30.92 Million | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more